Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
Símbolo de cotizaciónBDSX
Nombre de la empresaBiodesix Inc
Fecha de salida a bolsaOct 28, 2020
Director ejecutivoMr. Scott Hutton
Número de empleados273
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 28
Dirección919 West Dillon Road
CiudadLOUISVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal80027
Teléfono13034170500
Sitio Webhttps://www.biodesix.com/
Símbolo de cotizaciónBDSX
Fecha de salida a bolsaOct 28, 2020
Director ejecutivoMr. Scott Hutton
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos